JP2017526740A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526740A5 JP2017526740A5 JP2017527534A JP2017527534A JP2017526740A5 JP 2017526740 A5 JP2017526740 A5 JP 2017526740A5 JP 2017527534 A JP2017527534 A JP 2017527534A JP 2017527534 A JP2017527534 A JP 2017527534A JP 2017526740 A5 JP2017526740 A5 JP 2017526740A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- tumor
- poly
- agonist
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 222
- 239000000203 mixture Substances 0.000 claims description 61
- 206010028980 Neoplasm Diseases 0.000 claims description 41
- 239000000556 agonist Substances 0.000 claims description 26
- 239000003981 vehicle Substances 0.000 claims description 22
- 239000002105 nanoparticle Substances 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 229920002988 biodegradable polymer Polymers 0.000 claims description 14
- 239000004621 biodegradable polymer Substances 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 14
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 12
- 108010062374 Myoglobin Proteins 0.000 claims description 10
- 102000036675 Myoglobin Human genes 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 10
- 229920000642 polymer Polymers 0.000 claims description 10
- 230000001839 systemic circulation Effects 0.000 claims description 10
- 229920001400 block copolymer Polymers 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 8
- 229920001059 synthetic polymer Polymers 0.000 claims description 8
- 210000005166 vasculature Anatomy 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 6
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 6
- 229920001610 polycaprolactone Polymers 0.000 claims description 6
- 229920000575 polymersome Polymers 0.000 claims description 6
- 230000002000 scavenging effect Effects 0.000 claims description 6
- 101000635854 Homo sapiens Myoglobin Proteins 0.000 claims description 4
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 4
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 4
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims description 4
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims description 4
- 108091008605 VEGF receptors Proteins 0.000 claims description 4
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229920000249 biocompatible polymer Polymers 0.000 claims description 4
- 230000000740 bleeding effect Effects 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 238000006392 deoxygenation reaction Methods 0.000 claims description 4
- 238000009792 diffusion process Methods 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 229940065514 poly(lactide) Drugs 0.000 claims description 4
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 4
- 230000008685 targeting Effects 0.000 claims description 4
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 4
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 4
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 4
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 claims description 4
- 238000009825 accumulation Methods 0.000 claims description 3
- 230000000903 blocking effect Effects 0.000 claims description 3
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 2
- VNXMFQWTDCWMDQ-UHFFFAOYSA-N 5-methyloxepan-2-one Chemical compound CC1CCOC(=O)CC1 VNXMFQWTDCWMDQ-UHFFFAOYSA-N 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 102000008133 Iron-Binding Proteins Human genes 0.000 claims description 2
- 108010035210 Iron-Binding Proteins Proteins 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 206010047139 Vasoconstriction Diseases 0.000 claims description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 230000004087 circulation Effects 0.000 claims description 2
- 230000021615 conjugation Effects 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 230000010102 embolization Effects 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims description 2
- 239000000693 micelle Substances 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 230000017074 necrotic cell death Effects 0.000 claims description 2
- 230000035699 permeability Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- -1 poly (methyl ε-caprolactone Chemical compound 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 239000002534 radiation-sensitizing agent Substances 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 239000002356 single layer Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000002459 sustained effect Effects 0.000 claims description 2
- 210000001215 vagina Anatomy 0.000 claims description 2
- 230000025033 vasoconstriction Effects 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 19
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/455,082 | 2014-08-08 | ||
| US14/455,082 US20140363496A1 (en) | 2011-01-07 | 2014-08-08 | Compositions and Methods for Inducing Nanoparticle-mediated Microvascular Embolization of Tumors |
| PCT/US2015/044017 WO2016022805A1 (en) | 2014-08-08 | 2015-08-06 | Compositions and methods for inducing nanoparticle-mediated microvascular embolization of tumors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526740A JP2017526740A (ja) | 2017-09-14 |
| JP2017526740A5 true JP2017526740A5 (enExample) | 2018-07-19 |
| JP6764864B2 JP6764864B2 (ja) | 2020-10-07 |
Family
ID=55264557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017527534A Active JP6764864B2 (ja) | 2014-08-08 | 2015-08-06 | 腫瘍のナノ粒子媒介微小血管塞栓形成を誘導するための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3177713B1 (enExample) |
| JP (1) | JP6764864B2 (enExample) |
| AU (1) | AU2015301014B2 (enExample) |
| CA (1) | CA2957552C (enExample) |
| ES (1) | ES2822557T3 (enExample) |
| WO (1) | WO2016022805A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016149562A2 (en) | 2015-03-17 | 2016-09-22 | Omniox, Inc. | Modulation of tumor immunity by protein-mediated 02 delivery |
| US10456452B2 (en) | 2015-07-02 | 2019-10-29 | Poseida Therapeutics, Inc. | Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles |
| US11213594B2 (en) | 2016-04-29 | 2022-01-04 | Poseida Therapeutics, Inc. | Poly(histidine)-based micelles for complexation and delivery of proteins and nucleic acids |
| KR20250011252A (ko) | 2016-09-30 | 2025-01-21 | 포세이다 테라퓨틱스, 인크. | 변형된 줄기세포 기억 t 세포, 이의 제조 방법 및 사용 방법 |
| US20190119636A1 (en) | 2017-10-23 | 2019-04-25 | Poseida Therapeutics, Inc. | Modified stem cell memory t cells, methods of making and methods of using same |
| AU2017339511B2 (en) | 2016-10-06 | 2021-12-02 | Poseida Therapeutics, Inc. | Inducible caspases and methods for use |
| US10329543B2 (en) | 2017-10-23 | 2019-06-25 | Poseida Therapeutics, Inc. | Modified stem cell memory T cells, methods of making and methods of using same |
| US20230241184A1 (en) * | 2020-06-23 | 2023-08-03 | Virtech Bio, Inc | Compositions and Methods for Treating Hemorrhagic Shock |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5612310A (en) | 1993-05-24 | 1997-03-18 | Duke University | Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders |
| GB9624540D0 (en) * | 1996-11-26 | 1997-01-15 | Nycomed Imaging As | Compositions |
| EP1131106B1 (en) * | 1998-11-12 | 2009-06-24 | Novolytics Inc. | Compositions and methods for producing vascular occlusion |
| ES2232613T3 (es) * | 2000-04-26 | 2005-06-01 | Cellegy Pharmaceuticals, Inc | Formulaciones y metodos de utilizacion de agentes mimeticos del oxido nitrico contra un fenotipo celular maligno. |
| WO2003022244A1 (en) * | 2001-09-12 | 2003-03-20 | Virexx Research, Inc. | Vascular occlusion solid-phase agent with immobilised platelet binding agent |
| KR101925436B1 (ko) * | 2008-04-10 | 2018-12-05 | 버지니아 커먼웰스 유니버시티 | 암 치료를 위한 종양 저 산소 상태의 유도 |
| US9044454B2 (en) * | 2010-03-10 | 2015-06-02 | Northwestern University | Regulation of microvasculature occlusion |
| US8808748B2 (en) * | 2010-04-20 | 2014-08-19 | Vindico NanoBio Technology Inc. | Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same |
| ES2718308T3 (es) * | 2011-01-07 | 2019-07-01 | Poseida Therapeutics Inc | Composiciones y métodos para la administración a tumores de agentes de unión de alta afinidad al oxígeno |
-
2015
- 2015-08-06 JP JP2017527534A patent/JP6764864B2/ja active Active
- 2015-08-06 WO PCT/US2015/044017 patent/WO2016022805A1/en not_active Ceased
- 2015-08-06 CA CA2957552A patent/CA2957552C/en active Active
- 2015-08-06 ES ES15829211T patent/ES2822557T3/es active Active
- 2015-08-06 EP EP15829211.0A patent/EP3177713B1/en active Active
- 2015-08-06 AU AU2015301014A patent/AU2015301014B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017526740A5 (enExample) | ||
| Narmani et al. | Biomedical applications of PLGA nanoparticles in nanomedicine: advances in drug delivery systems and cancer therapy | |
| Pushpalatha et al. | Nanocarrier mediated combination drug delivery for chemotherapy–A review | |
| Li et al. | Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancer | |
| Zhang et al. | The effect of autophagy inhibitors on drug delivery using biodegradable polymer nanoparticles in cancer treatment | |
| Ponce et al. | Hyperthermia mediated liposomal drug delivery | |
| Zhu et al. | Applications of nanoparticles for anticancer drug delivery: a review | |
| Wang et al. | An overview of nanotoxicity and nanomedicine research: principles, progress and implications for cancer therapy | |
| CN108136023B (zh) | 血小板膜包覆的药物递送系统 | |
| Zhang et al. | Drug delivery systems for differential release in combination therapy | |
| Ni et al. | Superior intratumoral penetration of paclitaxel nanodots strengthens tumor restriction and metastasis prevention | |
| US11730765B2 (en) | Platelet compositions and methods for the delivery of therapeutic agents | |
| Zhang et al. | Autocatalytic Delivery of Brain Tumor–Targeting, Size‐Shrinkable Nanoparticles for Treatment of Breast Cancer Brain Metastases | |
| JP6764864B2 (ja) | 腫瘍のナノ粒子媒介微小血管塞栓形成を誘導するための組成物および方法 | |
| US20130022545A1 (en) | DRUG DELIVERY SYSTEM FOR TREATMENT OF LIVER CANCER BASED ON INTERVENTIONAL INJECTION OF TEMPERATURE AND pH-SENSITIVE HYDROGEL | |
| Krishnamoorthy et al. | Polymersomes as an effective drug delivery system for glioma–a review | |
| Pavan et al. | Advanced cisplatin nanoformulations as targeted drug delivery platforms for lung carcinoma treatment: A review | |
| Jeswani et al. | Advances in the delivery of cancer therapeutics: a comprehensive review | |
| Talevi et al. | Applications of nanosystems to anticancer drug therapy (Part I. Nanogels, nanospheres, nanocapsules) | |
| Al-Amili et al. | Self-assembled micelles of amphiphilic PEGylated drugs for cancer treatment | |
| KR102348180B1 (ko) | 색전술용 마이크로캐리어 및 그 제조방법 | |
| Srinivasan et al. | Nanobiomaterials in cancer therapy | |
| Jablonowski et al. | Manipulating multifaceted microbubble shell composition to target both TRAIL‐sensitive and resistant cells | |
| Wang et al. | Crizotinib loaded polydopamine–polylactide-TPGS nanoparticles in targeted therapy for non-small cell lung cancer | |
| Levy et al. | The application of biomaterials in the treatment of platinum‐resistant ovarian cancer |